| Filed On | Filing |
|---|---|
| 07 Oct 2026 | SCHEDULE 13G |
| 17 Sep 2026 | SCHEDULE 13G |
| 14 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
Introductory. Yarrow Bioscience, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 5,769,231 shares of its common stock, par valu... |
| 11 Sep 2026 | 424B5 |
| 11 Sep 2026 | 424B5 |
| 10 Sep 2026 |
8-K: Other Events
1 Bringing life into balance Yarrow Bioscience Overview September 2026 |
| 19 Aug 2026 | EFFECT |
| 14 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | POS AM |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 |
8-K/A: Results of Operations and Financial Condition; Regulation FD Disclosure
Defined terms included below shall have the same meaning as terms defined and included elsewhere in the Combined Company’s (as defined below) Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) o... |
| 07 Aug 2026 | SCHEDULE 13G/A |
| 07 Aug 2026 | SCHEDULE 13G |
| 05 Aug 2026 | SCHEDULE 13D |
| 04 Aug 2026 | SCHEDULE 13G |
| 03 Aug 2026 | SCHEDULE 13G |
| 30 Jul 2026 | SCHEDULE 13G |
| 30 Jul 2026 |
Form 4: Rtw Fund Group GP, Llc, 10% owner and 1 other
Disposed of 133,290 shares (Other Transaction) · Acquired 133,290 Pre-Funded Warrants (Right to Buy) (Other Transaction) |
Loading...
